Fluoropyrimidines plus cisplatin versus gemcitabine/ gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma-a retrospective study

Journal of Gastrointestinal and Liver Diseases

Volumn 21, Issue 3, 2012, Pages 277-284

  Croitoru, Adina ^a   Gramaticu, Iulia ^a   Dinu, Ioana ^a   Gheorghe, Liana ^a   Alexandrescu, Sorin ^a   Buica, Florina ^a   Luca, Ioana ^a   Becheanu, Gabriel ^a   Herlea, Vlad ^a   Simionov, Iulia ^a   Hrehoret, Doina ^a   Lupescu, Ioana ^a   Popescu, Irinel ^a   Diculescu, Mircea ^a  

^a FUNDENI CLINICAL INSTITUTE   (Romania)

Author keywords

Advanced biliary tract cancer; Cisplatin; Fluoropyrimidines; Gemcitabine; Second line chemotherapy

Indexed keywords

CISPLATIN; FLUOROPYRIMIDINE; GEMCITABINE;

ADULT; ADVANCED CANCER; ARTICLE; BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GALLBLADDER CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; BILE DUCTS, INTRAHEPATIC; CARCINOMA; CHOLANGIOCARCINOMA; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GALLBLADDER NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84866518293     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005; 366: 1303-1314.
2. Hezel AF, Zhu AX. Systemic therapy for biliary tract cancers. Oncologist 2008; 13: 415-423.
3. Furuse J, Okusaka T, Bridgewater J, et al. Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer. Crit Rev Oncol Hematol 2011;80:31-39.
4. Mihalache F, Tantau M, Iancu C, Bodea R, Parau A, Acalovschi M. Therapeutic approach to the malignant tumors of the biliary tract. Rom J Intern Med 2010; 48: 131-140.
5. Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 2010; 103: 469-474.
6. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-1281.
7. Benson A.B. III, Abrams TA, Ben-Josef E, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw 2009;7:350-391.
8. Eckel F, Brunner T, Jelic S; ESMO Guidelines Working Group. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol 2011, 22 Suppl 6: vi40-vi44.
9. Kim MJ, Oh DY, Lee SH, et al. Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study. BMC Cancer 2008; 8: 374.
10. Kim TW, Chang HM, Kang HJ, et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol 2003; 14: 1115-1120.
11. Andre T, Tournigand C, Rosmorduc O, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 2004; 15: 1339-1343.
12. Charoentum C, Thongprasert S, Chewaskulyong B, Munprakan S. Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma. World J Gastroenterol 2007; 13: 2852-2854.
13. Dahan L, Bonnetain F, Ychou M, et al. Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). Gut 2010; 59: 1527-1534.
14. Doval DC, Sekhon JS, Gupta SK, et al. A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Br J Cancer 2004;90:1516-1520.
15. Furuse J, Takada T, Miyazaki M, et al. Guidelines for chemotherapy of biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg 2008; 15: 55-62.
16. Lee MA, Woo IS, Kang JH, Hong YS, Lee KS. Gemcitabine and cisplatin combination chemotherapy in intrahepatic cholangiocarcinoma as second-line treatment: report of four cases. Jpn J Clin Oncol 2004; 34: 547-550.
17. Meyerhardt JA, Zhu AX, Stuart K, et al. Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Dig Dis Sci 2008; 53: 564-570.
18. Thongprasert S, Napapan S, Charoentum C, Moonprakan S. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 2005; 16: 279-281.
19. Park JS, Oh SY, Kim SH, et al. Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study. Jpn J Clin Oncol 2005;35:68-73.
20. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825.
21. Lee S, Kim KH, Kim HJ, et al. Oxaliplatin, 5-FU, and leucovorin (FOLFOX) in advanced biliary tract cancer. ASCO Meeting 2011; 29: 4106 (abstract).
22. Mane J, Iruarrizaga E, Rubio I, et al. Second-line chemotherapy with capecitabine (CAP) and oxaliplatin (OX) in patients with pancreatic or biliary tree adenocarcinoma (ADC). ASCO Meeting 2011; 29: 308 (abstract).
23. Lee S, Oh SY, Kim BG, et al. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. Am J Clin Oncol 2009;32: 348-352.
24. Reni M, Pasetto L, Aprile G, et al. Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br J Cancer 2006; 94: 785-791.
25. Suzuki E, Ikeda M, Okusaka T, et al. A multicenter phase II of S-1 in gemcitabine-refractory biliary tract cancer. ASCO Meeting 2010; 28: 4145 (abstract).
26. Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007;96:896-902.
27. Valle JW. Advances in the treatment of metastatic or unresectable biliary tract cancer. Ann Oncol 2010; 21 Suppl 7: vii345-vii348.
28. Zhu AX, Hong TS, Hezel AF, Kooby DA. Current management of gallbladder carcinoma. Oncologist 2010; 15: 168-181.
29. Gallardo J, Rubio B, Villanueva L, Barajas O. Gallbladder cancer, a different disease that needs individual trials. J Clin Oncol 2005; 23: 7753-7754.
30. Abahssain H, Afchain P, Melas N, et al. Chemotherapy in gallbladder carcinoma. Presse Med 2010; 39: 1238-1245.
31. Treekitkarnmongkol W, Suthiphongchai T. High expression of ErbB2 contributes to cholangiocarcinoma cell invasion and proliferation through AKT/p70S6K. World J Gastroenterol 2010; 16: 4047-4054.
32. Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol 2010; 28: 3531-3540.